Bausch Health Reports Strong Financial Performance in 2024

Bausch Health Companies Inc. reported continued financial growth for the seventh consecutive quarter. Fourth quarter consolidated revenues reached $2.56 billion, a 6% increase from the previous year, and an increase of 9% on an organic basis. For the entire year, consolidated revenues were $9.63 billion, up 10% reported and 8% organically, showcasing growth across all segments.

The company reported a GAAP net income of $93 million for the fourth quarter but a net loss of $46 million for the year. Adjusted EBITDA increased to $935 million for the quarter and $3.31 billion for the year, reflecting 8% and 10% increases, respectively. This strong performance was driven by strategic investments and growth in key segments like Salix and Solta Medical.

Looking ahead, Bausch Health's guidance for 2025 projects revenues between $9.9 billion and $10.15 billion, with anticipated growth of up to 6% and Adjusted EBITDA growth up to 7%. The company also highlighted key R&D developments and financing strategies to further strengthen its portfolio and market position.